Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
Tolvaptan (TLV), an oral non-peptide antagonist of vasopressin V2 receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its possib...
Saved in:
Main Authors: | Te-Ling Lu (Author), Wei-Ting Chang (Author), Chee-Hong Chan (Author), Sheng-Nan Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hyponatremia: A role for vasopressin receptor antagonists?
by: Gourishankar Ramesh
Published: (2018) -
Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
by: Yasukatsu Izumi, et al.
Published: (2014) -
Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor
by: Shota Hiroshima, et al.
Published: (2021) -
New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception
by: Taka-aki Koshimizu, et al.
Published: (2009) -
New Topics in Vasopressin Receptors and Approach to Novel Drugs: Role of the Vasopressin Receptor in Psychological and Cognitive Functions
by: Nobuaki Egashira, et al.
Published: (2009)